REFERENCE FILE
Liraglutide
Examine the reference details alongside the questions and dated sources.
Reference details
Status as of
- Regulatory category
- Approved product
- Evidence category
- Randomized evidence
- Mechanism
- Activates the GLP-1 receptor.
- Evidence
- Randomized trials.
- Limitations
- Check other products separately.
- Safety
- The label warns about severe gastrointestinal reactions.
- Formulation and route
- Subcutaneous injection.
- Approval scope
- Saxenda: weight management for eligible patients.
READING NOTES
Questions for a closer look
Use a liraglutide paper to separate questions about authorship from questions about the argument. Read the affiliations and disclosures, then select a conclusion and trace its supporting measurement, comparison and reasoning. Keep a note about each author's stated role beside, rather than in place of, that reconstruction. Try a counterfactual reading: if the institutional names were hidden, which part of the argument would still need checking? Restore the names and ask whether they suggest a specific additional question about responsibility or access to records. The result should be a focused inquiry, not a verdict inferred from an affiliation.
Questions to investigate
- Which stated role connects an author to the analysis being discussed?
- What would I still need to verify if the affiliations were hidden?
- Does a disclosure suggest a specific question about responsibility or access?
Sources for this file
- SAXENDANLM · Checked
MED CONSUMER WATCH · RESEARCH
Read the evidence behind the question.
Browse reference files or follow a study analysis from its question to its limitations.